RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
RenovoRx will release Q3 2026 financial results and business highlights after market close on November 5, 2026, followed by a conference call at 4:30 p.m. ET. Management plans to discuss commercial execution of the FDA-cleared RenovoCath device and clinical progress on the TAMP platform, including the fully enrolled Phase III TIGeR-PaC trial of IAG, with topline data expected in the second half of 2027. Background figures cited include roughly $1.1 million in 2025 RenovoCath sales and record quarterly revenue of $909,000 in Q2 2026.
Key figures
- Q2 2026 revenue
- 909000
- Earnings call date
- November 5, 2026, 4:30 p.m. ET
- Renovocath 2025 sales
- $1.1 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.